Can creatinine kinase (CK) be elevated in Multiple Sclerosis (MS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Yes, creatinine kinase (CK) can be elevated in some patients with Multiple Sclerosis (MS), though it is not a typical diagnostic marker for the disease. CK elevation in MS patients is generally mild to moderate and occurs most commonly during acute relapses or exacerbations of the disease. This elevation typically reflects muscle damage that may result from spasticity, immobility, or as a secondary effect of inflammatory processes affecting muscle tissue. The pattern of CK elevation in MS differs from conditions like muscular dystrophies or rhabdomyolysis, where CK levels are often significantly higher. When elevated CK is found in an MS patient, clinicians should consider other potential causes such as medication side effects (particularly from statins), recent seizures, trauma, or vigorous exercise. Monitoring CK levels may be useful in some MS patients, especially those with muscle symptoms or those taking medications with potential muscle-related side effects, but CK measurement is not part of routine MS monitoring or diagnostic protocols. If unexpectedly high CK levels are found in an MS patient, further investigation for alternative or coexisting conditions is warranted, as suggested by various studies on MS management, including those on spasticity treatment 1, 2, 3, 4. Some studies have focused on the treatment of spasticity in MS, highlighting the use of medications like baclofen and tizanidine 5, but none directly address CK elevation in the context of MS. Given the potential for muscle damage and the importance of monitoring for complications, clinicians should be aware of the possibility of CK elevation in MS patients and investigate accordingly. Key considerations in the management of MS patients with elevated CK include:

  • Identifying and addressing potential causes of CK elevation
  • Monitoring for muscle-related side effects of medications
  • Considering the role of spasticity and immobility in CK elevation
  • Investigating for alternative or coexisting conditions when CK levels are unexpectedly high.

References

Research

Spasticity management in multiple sclerosis.

Physical medicine and rehabilitation clinics of North America, 2013

Research

Botulinum Toxin Treatment in Multiple Sclerosis-a Review.

Current treatment options in neurology, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.